Cargando…
Contents of US Food and Drug Administration Refuse-to-File Letters for New Drug Applications and Efficacy Supplements and Their Public Disclosure by Applicants
IMPORTANCE: Before reviewing drug applications, the US Food and Drug Administration (FDA) conducts “filing reviews” to assess whether they are complete enough for full review. If the applications are incomplete, the FDA issues refuse-to-file (RTF) letters identifying deficiencies. The FDA does not m...
Autores principales: | Chahal, Harinder Singh, Mukherjee, Sanjana, Sigelman, Daniel W., Temple, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885096/ https://www.ncbi.nlm.nih.gov/pubmed/33587091 http://dx.doi.org/10.1001/jamainternmed.2020.8866 |
Ejemplares similares
-
Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021
por: Monge, Andrea N., et al.
Publicado: (2022) -
Comparison of content of FDA letters not approving applications for new drugs and associated public announcements from sponsors: cross sectional study
por: Lurie, Peter, et al.
Publicado: (2015) -
Impact of the US Food and Drug Administration registration of antiretroviral drugs on global access to HIV treatment
por: Chahal, Harinder Singh, et al.
Publicado: (2018) -
An Evaluation of US Food and Drug Administration’s Program to Register HIV Drugs for Use in Resource-Constrained Settings
por: Chahal, Harinder Singh, et al.
Publicado: (2019) -
The US Food and Drug Administration's tentative approval process and the global fight against HIV
por: Chahal, Harinder Singh, et al.
Publicado: (2017)